Tuesday, April 28

Plasma ADMA as Biomarker in Neonatal Persistent Pulmonary Hypertension

Signal observed that plasma asymmetric dimethylarginine (ADMA) levels are significantly elevated in neonates with persistent pulmonary hypertension compared to controls and correlate with disease severity markers including oxygenation index and echocardiographic parameters. Evidence suggests ADMA demonstrates good discriminatory performance for identifying severe PPHN and declining levels associate with clinical improvement following therapeutic interventions. Worth noting this endogenous nitric oxide synthase inhibitor may serve as a promising biomarker for risk stratification and monitoring in neonatal pulmonary hypertension.

Larger multicenter studies are warranted to validate these findings and explore its prognostic utility.

Relevance: Study of plasma ADMA as a biomarker in neonatal persistent pulmonary hypertension (PPHN). Directly relevant to pulmonary hypertension research interest and pediatric patient population, with focus on disease severity assessment and therapeutic response monitoring.

Lisdexamfetamine-Induced Stress Cardiomyopathy in Adolescent

Signal observed of stress cardiomyopathy development in a 17-year-old following intentional lisdexamfetamine overdose, presenting with sympathomimetic toxidrome and severe cardiac dysfunction requiring intubation and acute heart failure management. Evidence suggests extended-release stimulant ingestions can result in rapid-onset cardiac dysfunction within 24 hours. Worth noting this rare pediatric presentation of stress cardiomyopathy from toxin exposure, highlighting need for cardiac monitoring in sympathomimetic overdoses.

Providers should be vigilant and monitor for signs of cardiac dysfunction.

Relevance: Case report of stress cardiomyopathy from sympathomimetic overdose in 17-year-old pediatric patient. Directly addresses pediatric acute heart failure/cardiogenic shock, though from toxin exposure rather than congenital disease.

Furosemide vs Torsemide in Acute Heart Failure

Evidence suggests no statistically significant differences between intravenous furosemide and torsemide for all-cause mortality, in-hospital mortality, or length of hospital stay in adult acute heart failure patients. Signal observed that torsemide group had no in-hospital deaths compared to 11.4% in furosemide group, though this difference was not statistically significant. Worth noting both loop diuretics demonstrated similar clinical outcomes when titrated according to urinary sodium concentration.

Both furosemide and torsemide showed no statistically significant differences in all-cause mortality, in-hospital mortality, and length of hospital stay.

Relevance: Comparative study of intravenous furosemide versus torsemide in adult acute heart failure patients. Furosemide is in the profile formulary; while study is in adult population, findings regarding diuretic efficacy in heart failure inform pediatric practice.

Dapagliflozin Effects on Epicardial Adipose Tissue in HFpEF

Signal observed that dapagliflozin 10 mg daily significantly reduced epicardial adipose tissue volume in heart failure with preserved ejection fraction patients compared to standard care. Evidence suggests SGLT2 inhibitor use was associated with structural changes in this fat depot implicated in HFpEF pathophysiology. Worth noting this finding represents a possible mechanistic pathway that requires validation in randomized outcome-driven trials.

(NCT06510270) (first submitted date 15/7/2024, first posted date 19/7/2024).

Relevance: Clinical trial of dapagliflozin effects on epicardial adipose tissue in HFpEF patients. Related to heart failure research interest but focuses on SGLT2 inhibitor not in profile formulary; adult population.

Renal Biomarkers Predicting Outcomes in Cardiorenal Syndrome Type 2

Signal observed that cardiorenal syndrome type 2 affected 65% of patients hospitalized for decompensated heart failure and was associated with doubled in-hospital and three-month mortality rates. Evidence suggests cystatin C and urinary albumin-to-creatinine ratio demonstrated moderate discriminative ability for predicting adverse outcomes including death or need for renal replacement therapy. Worth noting these renal biomarkers provided additional prognostic information beyond standard measures in this high-risk population.

Routine assessment of these biomarkers may provide additional prognostic information and support risk assessment in this high-risk population.

Relevance: Prospective study of renal biomarkers predicting outcomes in cardiorenal syndrome type 2 with decompensated HF. Related to heart failure research interest but in adult population; relevant to HF prognostication strategies.

Transcatheter Pulmonary Valve Interactions in Repaired Tetralogy of Fallot

Signal observed of an ongoing clinical trial at Boston Children's Hospital examining electroanatomic interactions between transcatheter pulmonary valve prostheses and anatomic isthmuses in 60 patients with repaired tetralogy of Fallot. Evidence suggests focus on understanding prosthesis performance and anatomical relationships in this congenital heart disease population. Worth noting this study directly addresses transcatheter interventions in a key diagnosis within the practice profile.

Relevance: Clinical trial directly evaluating transcatheter pulmonary valve prostheses in repaired tetralogy of Fallot (TOF), a profile diagnosis. Study examines electroanatomic interactions and prosthesis performance in pediatric/congenital population at Boston Children's Hospital. Highly relevant to profile interest in TOF management and pulmonary valve interventions.